ArticleAlzheimer's & dementia (New York, N. Y.)2019

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.

Michael Grundman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.